Bronchiectasis Epidemiology Forecast 2025-2034

Bronchiectasis is a chronic lung condition affecting an estimated 350,000 to 500,000 adults, characterised by the permanent widening and damage of the airways, leading to mucus build-up and recurrent infections. Post-infective bronchiectasis, often following severe respiratory infections, is the most common type, with asthma and COPD coexisting in 42% and 36% of cases, respectively. Prevalence estimates are higher in females (535/100,000) than males (467/100,000).

Bronchiectasis Epidemiology Forecast Report Coverage

The “Bronchiectasis Epidemiology Forecast Report 2025-2034” offers comprehensive information on the prevalence and demographics of bronchiectasis. It projects the future incidence and prevalence rates of bronchiectasis across various populations. The study covers age and type as major determinants of the bronchiectasis-affected population. The report highlights patterns in the prevalence of bronchiectasis over time and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on the epidemiology of bronchiectasis in the 8 major markets.

Regions Covered

• The United States
• Germany
• France
• Italy
• Spain
• The United Kingdom
• Japan
• India

Bronchiectasis Disease Overview

Bronchiectasis is a lung condition where the airways (bronchi) widen abnormally, leading to mucus build-up and recurrent infections. This damage prevents the airways from clearing mucus effectively, creating a cycle of inflammation, infections, and further airway damage. Common symptoms include a persistent cough, large amounts of phlegm, and breathlessness. Causes include infections, immune system disorders, or conditions like cystic fibrosis. The treatment focuses on managing symptoms, clearing mucus, preventing infections, and improving quality of life.

Bronchiectasis: Treatment Overview

Treatment for bronchiectasis focuses on managing symptoms, preventing infections, and improving lung function. Airway clearance techniques, such as chest physiotherapy and breathing exercises, help expel mucus. Medications include bronchodilators, mucus thinners, and antibiotics for infections, often delivered via inhalers or nebulizers. Vaccinations help reduce the risk of respiratory infections. Promising treatments from clinical trials include brensocatib, which has been shown to reduce bronchiectasis exacerbations by inhibiting neutrophil serine proteases, and BI1291583, which targets the respiratory microbiome. Alpha 1-proteinase inhibitors are also being studied for their potential to reduce airway inflammation. Severe cases may require pulmonary rehabilitation or surgery.

Epidemiology

The bonchiectasis epidemiology section offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. The publisher provides both current and predicted trends for bronchiectasis by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for bronchiectasis and their trends. The data is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.

• Bronchiectasis is more prevalent in women, with studies reporting proportions ranging from 51.6% to 68.0%.
• Prevalence increases significantly with age, rising from 4.2-43.4 per 100,000 people aged 18-34 years to 153-1,365 per 100,000 in those aged over 65-75 years.
• The mean age of bronchiectasis patients has increased over time, shifting from 61 to 68 years in the United States and from 64.2 to 67.6 years in Germany.
• Among all the identified cases of bronchiectasis, nearly 40% are idiopathic bronchiectasis.

Country-wise Bronchiectasis Epidemiology

The bronchiectasis epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

The epidemiology of bronchiectasis varies globally due to factors like age, smoking, and healthcare access. In the United States, 350,000-500,000 adults are affected, with prevalence rising from 4.2-43.4 per 100,000 in younger adults to 153-1,365 per 100,000 in those over 65-75 years. In the UK, over 500 per 100,000 people are affected, with prevalence increasing over the past 20 years due to improved diagnostic techniques and definitions. Prevalence is highest among older adults.

Scope of the Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of bronchiectasis based on several factors.
• Bronchiectasis Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The report helps to identify the patient population and the unmet needs of bronchiectasis are highlighted along with an assessment of the disease's risk and burden.

Key Questions Answered

• What are the key findings of bronchiectasis epidemiology in the 8 major markets?
• What will be the total number of patients with bronchiectasis across the 8 major markets during the forecast period?
• What was the country-wise prevalence of bronchiectasis in the 8 major markets in the historical period?
• Which country will have the highest number of bronchiectasis patients during the forecast period of 2025-2034?
• Which key factors would influence the shift in the patient population of bronchiectasis during the forecast period of 2025-2034?
• What are the currently available treatments for bronchiectasis?
• What are the disease risks, signs, symptoms, and unmet needs of bronchiectasis?

This product will be delivered within 3-5 business days.